Fig. 1

Exposure-adjusted IRs of TEAEs, SAEs, and selected AEs (Exposure Safety Populations) across indications over successive year intervals; PsO (year 0 to year 5) PsA (year 0 to year 3), axSpA (including patients with AS and nr-axSpA) (year 0 to ≥ 2). The data points on the graph are the IR (95% CI)/100 PY. The CIs for the IRs are from likelihood ratio test of treatment effect from the Poisson regression model. All studies were conducted using the original, citrate-containing formulation of IXE. Abbreviations: axSpA, axial spondyloarthritis; IBD, inflammatory bowel disease; CI; confidence interval; IR, incidence rate per 100 patient-years; ISR, injection site reaction IXE; ixekizumab; MACE, major adverse cerebro-cardiovascular event; N, number of patients in the analysis population; n, number of patients in each category; PsA, psoriatic arthritis; PsO, psoriasis; SAE, serious adverse event; TEAE, treatment-emergent adverse event